Skip to main content

Table 4 Multimodal treatment strategy of CUA: initiation and modifications of treatments after CUA diagnosis

From: Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study

Treatment

N

Total CUA cases

N

Dialysis cases

N

Non dialysis cases

Wound care

89

88 (98.9%)

70

70 (100.0%)

19

18 (94.7%)

Antibiotherapy

89

69 (77.5%)

70

53 (75.7%)

19

16 (84.2%)

Discontinuation of VKA

65

46 (70.8%)

54

38 (70.4%)

11

8 (72.7%)

Discontinuation of active vitamin D

20

14 (70.0%)

17

11 (64.7%)

3

3 (100.0%)

Intravenous STS

89

58 (65.2%)

70

45 (64.3%)

19

13 (68.4%)

 STS cumulative dose (g)

56

488 (300–750)

43

525 (300–750)

13

375 (225–900)

 STS duration (week)

58

6 (4–10)

45

6 (4–10)

13

5 (3–12)

Renal Replacement Therapy modification

89

57 (64.0%)

    

 Increase of dialysis duration and/or frequency

  

70

41 (58.6%)

  

 Start of dialysis

    

19

16 (84.2%)

 Switch from HD to HDF

  

70

13 (18.6%)

  

 Switch from HDF to HD

  

70

4 (5.7%)

  

 Use of citrate dialysate

89

6 (6.7%)

70

6 (8.6%)

19

0 (0.0%)

Discontinuation or lowering of oral calcium supply

53

31 (58.5%)

46

26 (56.5%)

7

5 (71.43%)

Nutritional support therapy

89

47 (52.8%)

70

35 (50.0%)

19

12 (63.2%)

Sevelamer

89

42 (47.2%)

70

31 (44.3%)

19

11 (57.9%)

 Initiation or dose increase of Sevelamer

89

24 (27.0%)

70

15 (21.4%)

19

9 (47.4%)

Initiation or dose increase of Cinacalcet

89

31 (34.8%)

70

27 (38.6%)

19

4 (21.1%)

Discontinuation of native vitamin D

52

18 (34.6%)

40

12 (30.0%)

12

6 (50.0%)

Surgical debridement

89

22 (24.7%)

70

17 (24.3%)

19

5 (26.3%)

 ≥ 2 surgical debridement

89

9 (10.1%)

70

8 (11.4%)

19

1 (5.26%)

Amputation

89

15 (16.9%)

70

13 (18.6%)

19

2 (10.5%)

 Lanthanum carbonate

89

15 (16.9%)

70

15 (21.4%)

19

0 (0.0%)

 Initiation or dose increase of Lanthanum carbonate

89

7 (7.9%)

70

7 (10.0%)

19

0 (0.0%)

 Negative pressure wound therapy

89

12 (13.5%)

70

8 (11.4%)

19

4 (21.1%)

 Discontinuation of iron therapy

62

8 (12.9%)

54

7 (13.0%)

8

1 (12.5%)

 Standard oxygen therapy

89

11 (12.4%)

70

9 (12.9%)

19

2 (10.5%)

 Initiation or dose increase of statin

89

10 (11.2%)

70

8 (11.4%)

19

2 (10.5%)

 Skin transplantation

89

8 (9.0%)

70

7 (10.0%)

19

1 (5.3%)

Parathyroidectomy

89

5 (5.6%)

70

5 (7.1%)

19

0 (0.0%)

Steroids

 Discontinuation or dose decrease of steroids

12

7 (58.3%)

10

6 (60.0%)

2

1 (50.0%)

 Initiation or dose increase of steroids

12

2 (16.7%)

10

2 (20.0%)

0

0 (0.0%)

 Local steroids treatement

89

12 (13.5%)

70

9 (12.9%)

19

3 (15.8%)

  1. Median (IQR) or N (%). HD hemodialysis, HDF hemodiafiltration, STS sodium thiosulfate, VKA vitamin K antagonist